数据
资源
版本对比
免费注册
预约演示
免费注册
Microbix
Presenting Test-Workflow Validation Results at EMMDMSwab® & PROCEEDx™FLOQ® Supporting Self-Collection for HPV Screening Programs
2022-10-06
·
BioSpace
财报
抗体
MISSISSAUGA, Ontario, Oct. 06, 2022 (GLOBE NEWSWIRE) --
Microbix Biosystems Inc.
(TSX: MBX, OTCQX: MBXBF,
Microbix
®), a life sciences innovator, manufacturer, and exporter, announces that, on behalf of Santina Castriciano of Copan Italia S.p.A. and in collaboration with Victorian Cytology Service of the Australian Centre for the Prevention of
Cervical Cancer
(VCS Pathology), it will present results of novel methods to support diagnostic accuracy and whole-process workflow validation of
cervical cancer
screening tests on self-collected patient specimens. The poster presentation will be made at the 12th European Meeting on Molecular Diagnostics (“EMMD”) taking place in Noordwijk, Netherlands from October 12 to 14, 2022. Ample evidence supports use of self-collected vaginal samples to improve participation in
cervical cancer
screening programs based on molecular (“MDx”) detection of Human Papilloma Virus (“HPV”). However, broad adoption of self-collection has been set-back by a lack of materials and methods to evaluate the whole workflow experienced by a specimen – from collection to final diagnostic result. This critical gap is bridged by the current study using
Microbix
PROCEEDx™FLOQ® simulated positive HPV samples eluted into Copan MSwab® medium – evaluating whether HPV was effectively eluted from the simulated self-collected swabs and then detected by commercial in vitro diagnostic (“IVD”) PCR-based MDx assays. The study determined that three positive specimens simulating
infection
with high-risk HPV types (16, 18 & 45) and a negative sample were detected and individually identified on six IVD MDx assays: the Abbott Alinity m HPV & Abbott Realtime HPV, Qiagen NeumoDx HPV,
Roche
cobas 4800 HPV &
Roche
cobas 6800 HPV, and Seegene Anyplex II HPV28. Accuracy was 100% across all sample types and assays. The poster will be available on
Microbix
’s website ( ) and from EMMD after its presentation. HPV represents a family of over 100 virus sub-types, of which 14 are deemed “high-risk” as they are proven to directly cause
cancers
, including but not limited to
cervical cancer
. Most sexually-active adults become infected with one or more types of HPV and such
infections
can be persistent. MDx tests permit early detection and guide timely preventative healthcare by identifying those at-risk years before the development of
cancers
. However, MDx-based screening programs require rigorous workflow design and ongoing validation to ensure their accuracy. Many healthcare systems now plan to resume the roll-out of MDx-based HPV screening programs that were delayed as a result of the
COVID-19 pandemic
, important diagnostic healthcare advancements that
Microbix
is pleased to support with its products and services. Empowering women to collect vaginal samples in private, safe, and convenient locations is expected to promote patient access to healthcare and accelerate the widespread adoption of MDx-based HPV and
cervical cancer
screening programs.
Microbix
is proud to be a strategic partner of Copan and help to accelerate the evolution to self-collection by offering HPV-oriented “PROCEED™FLOQ®” (RUO) and prospective “REDx™FLOQ®” (IVD) quality assessment products (QAPs™) worldwide. Purchase enquiries for
Microbix
’s QAPs can be e-mailed to customer.service@microbix.com. About
Microbix Biosystems
Microbix
develops proprietary biological products and services for human health and well-being, with over 100 skilled employees and sales approaching C$ 2.0 million per month. It makes a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™ IVD or RUO test-controls) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows.
Microbix
antigens enable the antibody tests of over 100 international diagnostics companies, while its QAPs are sold to clinical laboratory accreditation organizations, diagnostics companies, and clinical laboratories.
Microbix
QAPs are now available in over 30 countries, distributed by 1WA (
Oneworld Accuracy Inc.
),
Alpha-Tec Systems, Inc.
,
Diagnostic International Distribution SpA.
, Labquality Oy, The Medical Supply Company of Ireland,
R-Biopharm AG
,
SDT Molecular Pte Ltd
, Seegene Canada Inc., and
Thomas Scientific LLC
.
Microbix
is ISO 9001 and 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides CE marked products.
Microbix
also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably viral transport medium (DxTM™) to stabilize patient samples for lab-based molecular diagnostic testing and
Kinlytic
®
urokinase
, a biologic thrombolytic drug used to treat blood clots.
Microbix
is traded on the TSX and OTCQX, and headquartered in Mississauga, Ontario, Canada. Forward-Looking Information This news release includes “forward-looking information,” as such term is defined in applicable securities laws. Forward-looking information includes, without limitation, discussion of Copan, HPV, EMMD, or VCS, the poster or its relevance, the products of
Microbix
or its collaborators,
Microbix
’s business and business results, goals or outlook, risks associated with financial results and stability, development projects such as those referenced in its corporate presentation, regulatory compliance and approvals, sales to foreign jurisdictions, engineering and construction, production (including control over costs, quality, quantity and timeliness of delivery), foreign currency and exchange rates, maintaining adequate working capital or raising further capital on acceptable terms or at all, and other similar statements concerning anticipated future events, conditions or results that are not historical facts. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking information is inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. All statements are made as of the date of this news release and represent the Company’s judgement as of the date of this new release, and the Company is under no obligation to update or alter any forward-looking information. Please visit or for recent
Microbix
news and filings. For further information, please contact
Microbix
at: Cameron Groome, CEO (905) 361-8910 Jim Currie, CFO (905) 361-8910 Deborah Honig, Investor Relations Adelaide Capital Markets (647) 203-8793 ir@microbix.com Copyright © 2022
Microbix
Biosystems Inc.
Microbix
®, DxTM™,
Kinlytic
®, PROCEEDx™, QAPs™, REDx™ and REDx™ Controls are trademarks of
Microbix Biosystems Inc.
PROCEEDx™FLOQ® and REDx™FLOQ® are trademarks of
Microbix Biosystems Inc.
in collaboration with
Copan Italia
S.p.A. Copan®, FLOQ®, FLOQSwab®, and MSwab® are trademarks of
Copan Italia
S.p.A. Other parties’ corporate or product names referenced herein may be the trademarks of their respective companies.
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Microbix Biosystems, Inc.
Thomas Scientific LLC
Diagnostic Biosystems, Inc.
[+7]
适应症
宫颈癌
感染
肿瘤
[+1]
靶点
-
药物
尿激酶
尿激酶 (丽珠集团丽珠制药厂)
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
热门报告
全球潜力靶点及FIC产品研究调研报告
智慧芽生物医药
肿瘤领域药物开发早期热门靶点研究报告(AACR 2023-2024)
智慧芽生物医药
siRNA药物Amvuttra专利调研实务指南
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务